STATCenter·
FDA panel confronting peptide controversy
Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
Read at STAT →
Health · 1 sources covering this
FDA panel confronting peptide controversy
Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/8c49ca6bdcd846ed69499a8681f7948c8f562db4" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="FDA panel confronting peptide controversy"></iframe>
